Amgen, Eli Lilly to scale up manufacturing of COVID-19 antibody therapies

By The Science Advisory Board staff writers

September 17, 2020 -- Eli Lilly and Amgen will collaborate on global antibody manufacturing to significantly increase the supply capacity of Lilly's potential COVID-19 therapies.

Currently, Lilly is evaluating several potential neutralizing antibodies, such as LY-CoV-555, for the prevention and/or treatment of COVID-19 as monotherapies or in combination. Through the collaboration, the companies will have the ability to quickly scale up production of antibody therapies that are successful in clinical testing and receive regulatory approval.

The companies hope to be able to produce millions of doses in 2021.


Copyright © 2020 scienceboard.net
 


Email Address:

First Name:

Last Name:

I have read and agree to the privacy policy and terms of service and wish to opt-in for ScienceBoard.net.